Evaluating the efficacy of rBmHATαc as a multivalent vaccine against lymphatic filariasis in experimental animals and optimizing the adjuvant formulation

Vaccine

Volumn 32, Issue 1, 2013, Pages 19-25

  Dakshinamoorthy, Gajalakshmi ^a   Kalyanasundaram, Ramaswamy ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

ADCC; Adjuvant; Alum; Brugia malayi; Lymphatic filariasis; TLR 4 agonist; Vaccine

Indexed keywords

AL 007; AL 019; AL007; AL019; ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; HYBRID PROTEIN; IMJECT ALUM; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; RBMHATALPHAC VACCINE; UNCLASSIFIED DRUG; VACCINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; EXPERIMENTAL ANIMAL; IMMUNOGENICITY; IN VIVO STUDY; INFECTION PREVENTION; LYMPHATIC FILARIASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VACCINATION;

ADCC; ADJUVANT; ALUM; BRUGIA MALAYI; LYMPHATIC FILARIASIS; TLR-4 AGONIST; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, HELMINTH; ANTIBODY SPECIFICITY; ANTIGENS, HELMINTH; BRUGIA MALAYI; DISEASE MODELS, ANIMAL; ELEPHANTIASIS, FILARIAL; HELMINTH PROTEINS; IMMUNIZATION; IMMUNOGLOBULIN G; MALE; MICE; SPLEEN; VACCINES;

EID: 84891940061     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.083     Document Type: Article

References (35)

1. World Health Report Bridging the gap. Report of the Director General 1995, World Health Organization, Geneva-3.
2. Dakshinamoorthy G., Samykutty A.K., Munirathinam G., Shinde G.B., Nutman T., Reddy M.V., et al. Biochemical characterization and evaluation of a Brugia malayi small heat shock protein as a vaccine against lymphatic filariasis. PLoS One 2012, 7(3):e34077.
3. Madhumathi J., Prince P.R., Anugraha G., Kiran P., Rao D.N., Reddy M.V., et al. Identification and characterization of nematode specific protective epitopes of Brugia malayi TRX towards development of synthetic vaccine construct for lymphatic filariasis. Vaccine 2010, 28(31):5038-5048.
4. Kalyanasundaram R., Balumuri P. Multivalent vaccine formulation with BmVAL-1 and BmALT-2 confer significant protection against challenge infections with Brugia malayi in mice and jirds. Res Rep Trop Med 2011, 2011(2):45-56.
5. Thirugnanam S., Pandiaraja P., Ramaswamy K., Murugan V., Gnanasekar M., Nandakumar K., et al. Brugia malayi: comparison of protective immune responses induced by Bm-alt-2 DNA, recombinant Bm-ALT-2 protein and prime-boost vaccine regimens in a jird model. Exp Parasitol 2007, 116(4):483-491.
6. Gnanasekar M., Rao K.V., He Y.X., Mishra P.K., Nutman T.B., Kaliraj P., et al. Novel phage display-based subtractive screening to identify vaccine candidates of Brugia malayi. Infect Immun 2004, 72(8):4707-4715.
7. Dakshinamoorthy G., Munirathinam G., Stoicescu K., Reddy M.V., Kalyanasundaram R. Large extracellular loop of tetraspanin as a potential vaccine candidate for filariasis. PLoS One 2013, October. 10. 1371/journal. pone. 0077394.
8. Dakshinamoorthy G., Samykutty A.K., Munirathinam G., Reddy M.V., Kalyanasundaram R. Multivalent fusion protein vaccine for lymphatic filariasis. Vaccine 2012.
9. Bartlett B.L., Tyring S.K. Safety and efficacy of vaccines. Dermatol Ther 2009, 22(2):97-103.
10. Curlin G., Landry S., Bernstein J., Gorman R.L., Mulach B., Hackett C.J., et al. Integrating safety and efficacy evaluation throughout vaccine research and development. Pediatrics 2011, 127(Suppl 1):S9-S15.
11. Wack A., Rappuoli R. Vaccinology at the beginning of the 21st century. Curr Opin Immunol 2005, 17(4):411-418.
12. Gupta R.K. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998, 32(3):155-172.
13. Sayers S., Ulysse G., Xiang Z., He Y. Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development. J Biomed Biotechnol 2012, 831486.
14. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9(4):287-293.
15. Schnare M., Barton G.M., Holt A.C., Takeda K., Akira S., Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001, 2(10):947-950.
16. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
17. Baldwin S.L., Shaverdian N., Goto Y., Duthie M.S., Raman V.S., Evers T., et al. Enhanced humoral and type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27(43):5956-5963.
18. Fox C.B., Friede M., Reed S.G., Ireton G.C. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem 2010, 53:303-321.
19. Abraham D., Grieve R.B., Holy J.M., Christensen B.M. Immunity to larval Brugia malayi in BALB/c mice: protective immunity and inhibition of larval development. Am J Trop Med Hyg 1989, 40:598-604.
20. Hem S.L., Johnston C.T., HogenEsch H. Imject® Alum is not aluminum hydroxide adjuvant or aluminum phosphate adjuvant. Vaccine 2007, 25(27):4985-4986.
21. Harris J.R., Soliakov A., Lewis R.J., Depoix F., Watkinson A., Lakey J.H. Alhydrogel(R) adjuvant, ultrasonic dispersion and protein binding: a TEM and analytical study. Micron 2012, 43(2-3):192-200.
22. Cain D.W., Sanders S.E., Cunningham M.M., Kelsoe G. Disparate adjuvant properties among three formulations of alum. Vaccine 2013, 31(4):653-660.
23. Jin B.R., Kim S.J., Lee J.M., Kang S.H., Han H.J., Jang Y.S., et al. Directly modulates Murine B lymphocytes to produce IgG1 isotype. Immune Network 2013, 13(1):10-15.
24. Reed S.G. Vaccine adjuvants. Expert Rev Vac 2013, 12(7):705-706.
25. McKee A.S., Burchill M.A., Munks M.W., Jin L., Kappler J.W., Friedman R.S., Jacobelli J., Marrack P. Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells. Proc Nat Acad Sci USA 2013 Mar 19, 110(12):E1122-E1131.
26. Hutchison S., Benson R.A., Gibson V.B., Pollock A.H., Garside P., Brewer J.M. Antigen depot is not required for alum adjuvanticity. FASEB J 2012 Mar, 26(3):1272-1279.
27. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
28. Richards R.L., Rao M., Wassef N.M., Glenn G.M., Rothwell S.W., Alving C.R. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect Immun 1998, 66(6):2859-2865.
29. Babu S., Ganley L.M., Klei T.R., Shultz L.D., Rajan T.V. Role of gamma Interferon and Interleukin-4 in host defense against the human filarial parasite Brugia malayi. Infect Immun 2000, 68:3034-3035.
30. Sharmila S., Christiana I., Kiran P., Reddy M.V., Kaliraj P. The adjuvant-free immunoprotection of recombinant filarial protein Abundant Larval Transcript- 2 (ALT-2) in Mastomys coucha and the immunoprophylactic importance of its putative signal sequence. Exp Parasitol 2011, 129(3):247-253.
31. Dash Y., Ramesh M., Kalyanasundaram R., Munirathinam G., Shultz L.D., Rajan T.V. Granuloma formation around filarial larvae triggered by host responses to an excretory/secretory antigen. Infect Immun 2011, 79(2):838-845.
32. Liu X.S., Leerberg J., MacDonald K., Leggatt G.R., Frazer I.H. IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host. J Immunol 2009, 183(1):51-58.
33. Hansen B., Sokolovska A., HogenEsch H., Hem S.L. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 2007, 25(36):6618-6624.
34. Alving C.R., Detrick B., Richards R.L., Lewis M.G., Shafferman A., Eddy G.A. Novel adjuvant strategies for experimental malaria and AIDS vaccines. Ann NY Acad Sci 1993, 690:265-275.
35. Edelman R. Vaccine adjuvants. Rev Infect Dis 1980, 2(3):370-383.